50% of patients with HRD respond to PARPi therapy (3). Moreover, patients without known HRD have also shown a clinical benefit from PARPis, as seen in recent trials assessing niraparib, olaparib, or rucaparib, as maintenance therapy in platinum-sensitive recurrent ovarian cancer (5-8). Given that not all patients will respond to PARPi therapy, improved clinical tools for predicting which patients will respond are urgently needed.
Introduction
Epithelial ovarian cancer (EOC) is the fifth deadliest malignancy in women, with more than 70% of patients presenting with advanced disease (1) . Until the recent emergence of targeted therapeutics, treatment has relied heavily on cytoreductive surgery and platinum/taxane-based chemotherapy (2) . Poly(ADP-ribose) polymerase inhibitors (PARPis) have emerged as promising drug candidates for the treatment of EOC. In current clinical practice, patients are commonly selected for PARPi therapy by testing positive for genetic mutations in genes encoding DNA repair proteins that result in homologous recombination deficiency (HRD), most notably mutations in breast and ovarian cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) (3, 4) . However, only approximatelyenhanced sensitivity to a DNA alkylating agent in WT cells, suggesting that loss of catalytic function could not be the only reason for PARPi efficacy (17) (18) (19) . Next, Murai et al. demonstrated that all clinically used PARPis have differential abilities to trap PARP-1 on DNA, but equally lack cytotoxicity in PARP1-KO -/-cells (22, 23) . While some PARPis are potent PARP-1 trappers, all PARPis target the PARP-1 enzyme, making it a potential prerequisite biomarker for efficacy (22) (23) (24) . Furthermore, PARP-1 has been development and application of PARPis, the primary drug target poly(ADP-ribose) polymerase 1 (PARP-1) has never been evaluated in vivo, even though loss of expression in vitro is a wellcharacterized resistance mechanism (3, (14) (15) (16) (17) (18) (19) . It was first hypothesized that PARPis work primarily through a synthetic lethality pathway where loss of BRCA1 or BRCA2 combined with chemical inhibition of PARP-1 results in cell death (20, 21) . However, it was later shown that deletion of PARP1 did not result in BRCA1-restored cells showed no increase in γH2AX compared with DMSO controls. Olaparib-treated OVCAR8 PARP1-KO G1 and G3 cells showed a 1.3 times increase (ANOVA, **P < 0.01 and ***P < 0.001, respectively) in γH2AX from DMSO controls. This was in contrast to olaparib-treated UWB1.289 and OVCAR8 cells that showed a 2.6 times (ANOVA, ****P < 0.0001) and 2.2 times (ANOVA, ****P < 0.0001) increase in γH2AX from DMSO controls. (E) Cell viability assays showed that PARP1-KO cells were equally resistant to olaparib compared with BRCA1-restored cells and all clinical PARP inhibitors required PARP-1 for maximum efficacy. Loss of PARP1 caused the greatest change in efficacy for niraparib and talazoparib. Cisplatin sensitivity was used as a positive control and remained unchanged after loss of PARP1. All in vitro experiments were completed 3 independent times. Cell lines shown in A-D, from left to right, are: UWB1.289, UWB1.289 BRCA1 restored, UWB1.289 PARP1-KO G1, UWB1.289 PARP1-KO G2, UWB1.289 PARP1-KO G3, OVCAR8, OVCAR8 PARP1-KO G1, OVCAR8 PARP1-KO G2, and OVCAR8 PARP1-KO G3. -, BRCA1 mutant. +, BRCA1 restored. I]KX1 quantify PARP-1 expression and have the ability to measure drug-target engagement of clinical PARPis by competing with one another for the NAD + binding pocket on the catalytic subdomain of PARP-1. Contrary to current methodologies that measure the biochemical product of PARP-1, poly(ADP-ribose) (PAR), this is a direct measurement of drug-target engagement.
In this work, we validate the preclinical rationale for measuring PARP-1 expression as a predictive biomarker of response to PARPis and report the first clinical trial studying PARP-1 expression with [ 
Results

CRISPR/Cas9 deletion of PARP1 in ovarian cancer cells.
Using CRISPR/Cas9 gene editing, we mediated the deletion of PARP1 in 2 ovarian cancer cell lines, one with a BRCA1 mutation and another with BRCA1 promoter methylation (UWB1.289 and OVCAR8). OVCAR8 cells have been previously shown to have reduced BRCA-1 expression attributed to promoter methylation and are sensitive to DNA-damaging agents (36) (37) (38) . Strikingly, the genetic deletion of PARP1 in EOC cells with a BRCA1 mutation or BRCA1 promoter methylation did not result in synthetic lethality, in that the cells were viable and grew in culture (21, 39) . Identifying the mechanism of viability was beyond the scope of this work, but is being pursued. Using this system for PARP1 deletion, we achieved more than 90% reduction of PARP-1 expression in polyclonal populations of BRCA1 mutant (UWB1.289) and BRCA1 methylshown by immunohistochemistry (IHC) to be highly variable in patients with ovarian (25) (26) (27) (28) , breast (29) , and prostate cancer (30) , irrespective of BRCA status. Together these studies demonstrate the need for a biomarker technology capable of quantitatively assessing PARP-1 in vivo that could enable patient selection for PARPi therapy.
Current methods to determine PARP-1 expression in clinical tumor specimens are limited and based on immunohistological methods that require invasive procedures such as biopsy or surgery. Association studies of PARP-1 expression by IHC with prognosis and outcome have demonstrated mixed results, suggesting inconsistency of staining procedures and antibodies (25) (26) (27) (28) . Indeed, there lacks a validated clinical IHC staining protocol for PARP-1 that can be widely and robustly applied in clinical practice (28) . Furthermore, approaches based on tissue sampling inadequately assess the potential heterogeneity of PARP-1 expression in disseminated EOC, a stage of disease highly relevant to PARPi therapy.
Radiotracer technology for the noninvasive imaging of PARP-1 could theoretically overcome the limitations of IHC by quantitatively assessing global PARP-1 expression in primary and disseminated disease (31, 32 Figure 1D ). Similarly, the same effect was observed in OVCAR8 cells ( Figure  1D ). Next, the cytotoxicity evaluated for clinically used PARPis showed that the loss of PARP1 resulted in equal or greater resistance compared with restoring BRCA1 in UWB1.289 cells ( Figure  1E , Supplemental Figure 2D , and Supplemental Cell microscopy studies showed that PARP-1 was indeed absent at the single-cell level in polyclonal populations ( Figure 1A and Supplemental Figure 1A ). We also examined PARP-2 and PARP-3 expression by Western blot to investigate off-target effects of single-guide RNAs. We found no differences from control for PARP-2 or PARP-3 expression by Western blot analysis (Supplemental Figure 1B ). Lastly, to determine whether PARP-1 expression varies among ovarian cell lines with and without BRCA dysfunction (Supplemental Table 1 ), we measured PARP-1 in multiple cell lines and demonstrated a dynamic range of expression (Supplemental Figure 2 , A and B, and Supplemental Table 2) . Table 2 ). Most notably, the deletion of PARP1 reduced radioligand binding of [ Table 4 and Supplemental Figure 5 ). PARP-1 expression was also positive in 2 lymph node samples, with residual disease on pathology, and costained with γH2AX. Finally, positive staining for PARP-1 and p53 co-occurred in 77% (10/13) of tissue samples, whereas positive staining for PARP-1 and γH2AX had 100% (13/13) co-occurrence (Supplemental Table 4 and Supplemental Figure 5 ).
The Journal of Clinical Investigation
C L I N I C A L M E D I C I N E
Clinical observations with [ Table 5 ). In follow-up, patient 2 showed disease progression within 4 months of therapy and was platinum resistant. In contrast, patient 11 had a BRCA1 mutation and showed low uptake on both [ Figure 3A ). In addition, tumor tissue analyzed from untreated and olaparib-treated mice by ex vivo autoradiography was used to confirm microPET findings ( Figure 2B and Supplemental Figure 3B ). Results between microPET imaging and ex vivo autoradiography were similar. Tumor-to-muscle ratios from microPET imaging before and after olaparib treatment were 4.2 ± 0.32 vs. 2.5 ± 0.11 (paired t test, P < 0.0025, n = 4) ( Figure 2C ). In agreement with microPET results, ex vivo autoradiographs showed a significant difference between untreated and olaparib-treated groups (5.14 ± 0.13 vs. 2.41 ± 0.18, unpaired t test, P < 0.0001, n = 2, 10 sections/ tumor) ( Figure 2D ). Autoradiographs also showed significant differences in tumor and muscle of untreated and olaparib-treated groups (unpaired t test, P < 0.0001) (Supplemental Figure 3C) .
Clinical trial enrollment. In this trial, 20 patients were enrolled and 10 patients who underwent surgical debulking or biopsy were included in the study. From the 10 patients, 13 tis- Table 5 ). Maximum SUVs of tumors ranged from as low as 2 (background) to as high as 12 and a similar range of PARP-1 expression was also observed by immunofluorescence and autoradiography ( Figure 7 , A and B, and Supplemental Table 5 ). Since [ (3, 14, 15, (17) (18) (19) 23) .
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In further support, we also observed a greater reduction in PARPi sensitivity with loss of PARP-1 expression compared with BRCA1 restoration in the UWB1.289 isogenic cell lines when treated with the potent PARP trappers, niraparib and talazoparib. This observation may have translational implications, since olaparib, rucaparib, and niraparib were recently approved by the FDA as maintenance therapy in platinum-sensitive patients, regard- PARP-1 expression may also play a role in predicting inherent or incurred DNA damage burden to identify DNA repair deficiencies or even treatment response as a functional biomarker of HRD (44, 45) . We are currently entering several clinical trials in both breast and ovarian cancer at the University of Pennsylvania to directly evaluate [ 
Methods
Study design. The objective of this study was to highlight the significance of PARP-1 expression for PARP inhibitor therapy using preclinical models of ovarian cancer and perform the first PET imaging study of PARP-1 in ovarian cancer using [ 18 F]FTT with histological correlates to confirm radiotracer uptake as a biomarker of PARP-1 expression. This goal was addressed by using CRISPR/Cas9 to delete PARP1 in models of ovarian cancer, which were then used to test PARPi efficacy in vitro. In addition, we used patient-derived orthotopic xenograft models of ovarian cancer to show proof of concept for [ 18 F]FTT microPET imaging of PARP-1 and PARPi drug-target engagement in less of BRCA mutation status (6) (7) (8) . These clinical reports suggest there is a need for predictive biomarkers for PARPi therapy that go beyond BRCA mutation and HRD testing. The direct measurement of the PARPi target, PARP-1 expression, described in this work offers a complementary approach that could strengthen genomic testing for predicting patient response to PARPi therapy.
We demonstrated that in addition to using radioligand binding as an in vitro assay of PARP-1 expression, the use of PET radiopharmaceuticals as an in vivo assay for PARP-1 is feasible in patients. This work reports the first clinical imaging trial in EOC using a PARP-1 radiotracer, [ Regardless of the exact mechanism in which PARPis induce anticancer effects, all current models require the drug target PARP-1 (15, 16, 23, 24) . This signifies the importance of quantitatively assessing the target of PARPis directly at the site of action by measuring intratumoral PARP-1 in primary and metastatic disease. We have shown in preclinical imaging studies that [ atin was also examined as a control to evaluate changes in sensitivity of DNA-damaging agents that occur after loss of PARP1. Cell viability was assessed using CellTiterGlo (Promega). Experiments were completed in duplicate 3 independent times. Preclinical microPET imaging of PARP-1. Through serial [
18 F]FTT PET imaging studies, we evaluated PARP-1 drug-target engagement using the FDA-approved PARPi olaparib. PET imaging of PARP-1 drug-target engagement is a noninvasive methodology to directly assess PARP inhibition. Using 2 ovarian cancer patient-derived xenograft models in 15-to 18-week-old female NOD SCID mice provided from the Simpkins laboratory at the University of Pennsylvania (48), including a BRCA1 mutant and WT, we performed microPET imaging on a Phillips Medical Systems scanner (n = 4 mice). Mice were imaged on day 1 and then olaparib was orally administered daily by gavage at a dose of 50 mg/kg. Mice were then reimaged on day 4, 1 hour after the fourth dose of olaparib. A total of 4 doses of olaparib was administered between imaging studies to achieve steady state. Ex vivo autoradiography studies were performed on mice from PDX model WO-12-2 with and without olaparib treatment (n = 6). The differences in tumor-tomuscle ratios were measured and were representative of the percentage of PARPi drug-target engagement.
PARP-1 immunohistochemistry and autoradiography on clinical specimens. Colormetric immunohistochemistry was performed at the University of Pennsylvania Pathology Core for H&E and biomarkers, including PARP-1, γH2AX, p53, LCA, and AE1/3. These biomarkers were chosen due to their relevance to EOC. AE1/3 is a keratin marker and was used to identify tumor cells by c-IHC. In order to determine where in the tumor microenvironment PARP-1 was expressed, we costained with LCA, which is a pan lymphocyte marker. In addition, we analyzed common biomarkers present in high-grade serous EOC, including p53 and γH2AX. Lastly, PARP-1 was evaluated by f-IHC and [ Statistics. Data presented are mean ± SEM unless otherwise noted. All graphs were produced and statistically analyzed using Prism version 6.0, GraphPad. The maximum number of PARP binding sites (B max ) was calculated by an exponential nonlinear curve-fit 1-site binding hyperbola function. All statistical tests comparing the mean of 2 groups were 2-sided. The comparisons of the means from more than 2 groups were performed using 1-way ordinary ANOVA. All in vitro experiments were carried out using a standard cell culture technique and repeated 3 independent times. The deletion of PARP1 with CRISPR/Cas9 was performed in 2 ovarian cancer cell lines. In addition, 3 unique guide RNAs were used to mediate the deletion of PARP1. Polyclonal populations of PARP1-KO cell lines were used to test PARPi efficacy in vitro. A sample size of 4 was selected for preclinical imaging studies to prevent bias greater than 10% for interpreting and analyzing microPET image results. No data from preclinical models was excluded from analyses.
For the clinical portion of this study, 20 patients with EOC were enrolled, 10 of whom had tissue available for in vitro analysis. Eight of those 10 underwent [ Table  5 ). All tissue specimens from patients who underwent [ Table  6 ). All experimental procedures for preclinical and clinical work are described in detail in the supplemental information.
CRISPR/Cas9 deletion of PARP1 in ovarian cancer cells. OVCAR8 cells were a gift from David M. Livingston (Dana Farber Cancer Institute, Boston, Massachusetts, USA). All other cell lines were available through ATCC or the Basser Center for BRCA (University of Pennsylvania, Philadelphia, Pennsylvania, USA) (Supplemental Table 1 ). PARP1 was deleted in UWB1.289 and OVCAR8 EOC cell lines that have reduced BRCA-1 expression through a deleterious mutation (UWB1.289) or promoter methylation (OVCAR8). These mutations are characterized elsewhere in the literature (46, 47 radiography studies and analyzed data. HW designed CRISPR/ Cas9 guides for PARP-1 and performed in vitro PARP1-KO experiments. RD analyzed clinical PET images. MDF administered the radiotracer to patients and interpreted PET images. DAP administered the radiotracer to patients and interpreted PET images. RAG designed in vitro experiments and composed the manuscript. DAM administered the radiotracer to patients, designed experiments, interpreted the data, and composed the manuscript. FS designed patient-derived xenograft models, recruited patients, performed surgeries and biopsies, and composed the manuscript. RHM designed radiotracers and experiments and composed the manuscript. LLL designed experiments, analyzed data, recruited patients, lead the clinical trial, and composed the manuscript.
Dose-response curves were fitted using a nonlinear sigmoidal doseresponse curve, and effective calculations for 50% reduction in cell viability were calculated. Image analysis was performed using PMOD software, and tumor-to-muscle ratios were calculated. Preclinical microPET imaging studies comparing tumor uptake of radiotracer were analyzed using a paired, 2-tailed t test. Autoradiography studies were analyzed using an unpaired 2-tailed t test. We chose an α of 0.05 (95% confidence interval) and data were deemed significant if P < 0.05. For correlations, the Pearson correlation coefficient was calculated and the data were considered statistically significant if P < 0.05. 
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